A data processing system based on bacterial resistance monitoring

Abstract

The present application relates to the field of microbial monitoring technology, and in particular to a data processing system based on bacterial resistance monitoring. The system includes: obtaining biofilm marker information and pathogen type information, analyzing biofilm marker information and pathogen type information, and judging whether the pathogens in the animal have formed a biofilm; if the pathogens have formed a biofilm, analyzing the biofilm marker information and determining the real-time biofilm state; obtaining antibiotic destruction product information, and determining the apparent drug resistance performance of the pathogens according to the antibiotic destruction product information and pathogen type information; analyzing the real-time biofilm state and apparent drug resistance performance, determining the actual drug resistance performance of the pathogens, and outputting the actual drug resistance performance for veterinary reference. The present application avoids the misleading effect of the resistance performance of bacteria caused by the influence of biofilm on the adjustment of veterinary treatment plans, and can significantly reduce the abuse of antibiotics while improving the effectiveness of subsequent treatment plans.

Description

Technical Field

[0001] The present application relates to the technical field of microbial monitoring, and in particular to a data processing system based on bacterial resistance monitoring. Background Art

[0002] With the development of modern medicine, antibiotics are widely used in animal husbandry. Antibiotics can effectively treat bacterial infections in farmed animals, reduce the morbidity and mortality of farmed animals, and ensure food safety while improving the economic benefits of animal husbandry.

[0003] The widespread use of antibiotics can cause pathogens to develop drug resistance and form resistant strains, making bacterial infections in farmed animals difficult to treat. Therefore, it is very important to accurately assess bacterial resistance and take timely corresponding measures. Existing bacterial resistance monitoring technology cannot accurately assess the current bacterial resistance when there are objective differences between bacterial resistance in animals and bacterial resistance in vitro, resulting in misjudgment of the bacterial resistance itself, which in turn leads to countermeasures with extremely limited effects. Summary of the invention

[0004] The present application provides a data processing system based on bacterial resistance monitoring to solve the above technical problems.

[0005] In a first aspect, the present application provides a data processing system based on bacterial resistance monitoring, the system comprising:

[0006] Obtaining biofilm marker information and pathogenic bacteria type information, analyzing the biofilm marker information and the pathogenic bacteria type information, and determining whether the pathogenic bacteria in the animal body form a biofilm;

[0007] If the pathogenic bacteria have formed a biofilm, analyzing the biofilm marker information to determine the real-time biofilm status;

[0008] Obtaining information on antibiotic destruction products, and determining the apparent drug resistance performance of the pathogenic bacteria according to the information on the antibiotic destruction products and the type information of the pathogenic bacteria;

[0009] The real-time biofilm status and the apparent drug resistance performance are analyzed to determine the actual drug resistance performance of the pathogenic bacteria, and the actual drug resistance performance is output for veterinary reference.

[0010] Through the above technical scheme, the biofilm marker information and the pathogenic bacteria type information are analyzed to determine whether the pathogenic bacteria have formed a biofilm. If the pathogenic bacteria have formed a biofilm, the biofilm marker information is analyzed to determine the real-time biofilm status. Then, by analyzing the real-time biofilm status and the apparent drug resistance performance, the actual drug resistance performance of the pathogenic bacteria is determined, and the actual drug resistance performance of the bacteria in the biofilm is clarified, so as to avoid misleading the veterinary treatment plan adjustment due to the drug resistance performance of bacteria affected by the biofilm. While improving the effectiveness of subsequent treatment plans, it can significantly reduce the abuse of antibiotics, thereby curbing the further development of bacterial resistance.

[0011] Optionally, the biofilm marker information includes extracellular polysaccharide information, and the analyzing the biofilm marker information and the pathogenic bacteria type information to determine whether the pathogenic bacteria in the animal body form a biofilm includes:

[0012] According to the pathogenic bacteria type information, the extracellular polysaccharide information is screened to determine the pathogenic bacteria polysaccharide information;

[0013] Analyzing the polysaccharide information of the pathogenic bacteria to determine the polysaccharide quantity information, polysaccharide particle distribution information and polysaccharide cross-linking information of the pathogenic bacteria;

[0014] Determining a biofilm index according to the polysaccharide quantity information, the polysaccharide particle distribution information and the polysaccharide cross-linking information;

[0015] The biofilm index is compared with a preset biofilm threshold value. If the biofilm index is greater than the preset biofilm threshold value, it is determined that the pathogenic bacteria in the animal have formed a biofilm.

[0016] Through the above technical scheme, the extracellular polysaccharide information is screened according to the pathogenic bacteria type information, the pathogenic bacteria polysaccharide information is determined, and then the polysaccharide quantity information, polysaccharide particle distribution information and polysaccharide cross-linking information of the pathogenic bacteria are obtained. After comprehensive analysis of the above information, the biofilm index is determined, and the biofilm index is compared with the preset biofilm threshold. If the biofilm index is greater than the preset biofilm threshold, it is determined that the pathogenic bacteria in the animal have formed a biofilm, so that the biofilm index can comprehensively reflect the biofilm formation state outside the current pathogenic bacteria, improve the accuracy of judging whether the pathogenic bacteria have formed a biofilm, and then ensure the accuracy of the subsequent evaluation of the actual drug resistance performance of the pathogenic bacteria in the biofilm.

[0017] Optionally, determining the biofilm index according to the polysaccharide quantity information, the polysaccharide particle distribution information and the polysaccharide cross-linking information includes:

[0018] Determining an average polysaccharide amount and a maximum polysaccharide amount according to the polysaccharide amount information;

[0019] Determining an average particle diameter and a particle diameter standard deviation according to the polysaccharide particle distribution information;

[0020] Determining an average cross-linking score, a maximum cross-linking score, and a minimum cross-linking score according to the polysaccharide cross-linking information;

[0021] The biofilm index is determined by the following formula:

[0022] ;

[0023] in, is the biofilm index, is the average polysaccharide amount, is the maximum polysaccharide amount, The preset quantity affects the weight. is the average particle diameter, is the particle diameter standard deviation, To preset particle influence weights, is the average cross-linking score, is the maximum value of the cross-linking score, is the minimum cross-linking score, Preset cross-link influence weight.

[0024] Through the above technical scheme, mathematical analysis methods are used to standardize and normalize the polysaccharide quantity information, polysaccharide particle distribution information and polysaccharide cross-linking information through mathematical formulas, and the biofilm index is calculated by weighted sum, making the biofilm index more comprehensive and accurate, thereby improving the accuracy of judging whether bacteria have formed a biofilm.

[0025] Optionally, analyzing the biofilm marker information to determine the real-time biofilm status includes:

[0026] Analyzing the polysaccharide information of the pathogenic bacteria to determine the polysaccharide viscosity, polysaccharide protein content, polysaccharide charge characteristics and polysaccharide hydration index;

[0027] Determining the real-time structural state index of the pathogenic bacteria according to the polysaccharide viscosity and the polysaccharide protein content;

[0028] Determining the real-time functional status index of the pathogenic bacteria according to the polysaccharide charge characteristics and the polysaccharide hydration index;

[0029] determining a biofilm state index according to the real-time structural state index and the real-time structural state index;

[0030] The biofilm state is determined according to the biofilm state index.

[0031] Through the above technical scheme, the polysaccharide viscosity, polysaccharide protein content, polysaccharide charge characteristics and polysaccharide hydration index are analyzed to obtain the real-time structural state index and the real-time functional state index respectively. The real-time structural state index and the real-time functional state index are combined to determine the biofilm index, and then the biofilm state is determined, so that the obtained biofilm state is consistent with the actual situation of the bacterial peripheral biofilm, thereby improving the accuracy of the subsequent analysis of the actual bacterial resistance process based on the biofilm state.

[0032] Optionally, the real-time structural state index of the pathogenic bacteria is determined according to the polysaccharide viscosity and the polysaccharide protein content, specifically the following formula:

[0033] ;

[0034] in, is the real-time structural status index, is the preset infrastructure status index, is the preset viscosity influence coefficient, is the viscosity of the polysaccharide, To preset the protein influence coefficient, To preset the protein impact index, is the protein content of the polysaccharide.

[0035] Through the above technical scheme, the nonlinear effects of polysaccharide viscosity and polysaccharide protein content on the structural state of the biofilm are comprehensively described through mathematical formulas, and then a real-time structural state index reflecting the real-time structural state of the biofilm is obtained, thereby improving the accuracy and comprehensiveness of the biofilm state determination process.

[0036] Optionally, the real-time functional status index of the pathogenic bacteria is determined according to the polysaccharide charge characteristics and the polysaccharide hydration index, specifically as follows:

[0037] ;

[0038] in, is the real-time functional status index, is the preset charge influence coefficient, is the preset charge fluctuation coefficient, is the charge characteristic of the polysaccharide, is the preset hydration influence coefficient, is the preset hydration fluctuation coefficient, is the polysaccharide hydration index;

[0039] The biofilm state index is determined according to the real-time structural state index and the real-time functional state index, specifically the following formula:

[0040] ;

[0041] in, is the biofilm status index, is the real-time structural status index, is the real-time functional status index.

[0042] Through the above technical scheme, on the basis of the polysaccharide charge characteristics and the polysaccharide hydration index, the influence of the periodic fluctuation of the polysaccharide charge characteristics and the stable fluctuation of the polysaccharide hydration index on the real-time functional status index is taken into consideration, and the influence of the polysaccharide charge characteristics and the polysaccharide hydration index on the real-time functional status index is comprehensively considered by using mathematical formulas to quantify and obtain an accurate real-time functional status index, thereby improving the comprehensiveness of the real-time functional status index.

[0043] Optionally, determining the apparent drug resistance performance of the pathogenic bacteria according to the information of the antibiotic destruction products and the information of the type of the pathogenic bacteria includes:

[0044] According to the pathogenic bacteria type information, the antibiotic destruction product information is screened to determine the pathogenic bacteria metabolite information;

[0045] Based on the pathogen type information, the pathogen metabolite information is subjected to drug resistance association analysis to determine the apparent drug resistance performance.

[0046] Through the above technical scheme, on the basis of the information on the type of pathogenic bacteria, the antibiotic destruction products are screened to determine the metabolite information of the pathogenic bacteria, and based on the metabolite information of the pathogenic bacteria, the apparent drug resistance performance is determined, so that the apparent drug resistance performance is consistent with the actual situation of the pathogenic bacteria, thereby improving the accuracy of the apparent drug resistance performance.

[0047] Optionally, analyzing the real-time biofilm state and the apparent drug resistance performance to determine the actual drug resistance performance of the pathogenic bacteria includes:

[0048] According to the real-time biofilm state, determining a number of state activity coefficients and biofilm state information;

[0049] Based on the apparent drug resistance performance, the actual drug resistance performance is determined according to the several state activity coefficients and the biofilm state information.

[0050] Through the above technical scheme, according to the real-time biofilm status, several state activity coefficients and biofilm status information are determined, and on the basis of the apparent drug resistance performance, according to several state activity coefficients and biofilm status information, the actual drug resistance performance is determined, and according to the different effects of different biofilm states on bacterial resistance, accurate actual drug resistance performance is obtained, so that the actual drug resistance performance conforms to the actual situation, thereby improving the accuracy and comprehensiveness of the actual drug resistance performance.

[0051] Optionally, the several state activity coefficients include an attached state activity coefficient, an aggregated state activity coefficient, a stable state activity coefficient and a diffused state activity coefficient, the biofilm state information includes an attachment degree, an aggregation degree, an effective antibiotic concentration and a diffusion membrane amount, and the actual drug resistance performance is determined based on the apparent drug resistance performance according to the several state activity coefficients and the biofilm state information, specifically as follows:

[0052] ;

[0053] in, For the actual drug resistance performance, For the manifestation of drug resistance, is the preset adhesion influence coefficient, is the attachment state activity coefficient, is the degree of adhesion, is the preset aggregation influence coefficient, is the degree of aggregation, is the aggregation state activity coefficient, is the preset stability influence coefficient, is the effective concentration of the antibiotic, is the steady-state activity coefficient, is the preset diffusion influence coefficient, is the diffusion membrane volume, is the diffusion state activity coefficient.

[0054] Through the above technical scheme, the mathematical formula is controlled by the attachment state activity coefficient, aggregation state activity coefficient, stable state activity coefficient and diffusion state activity coefficient for the current biofilm state of the bacteria. On the basis of the apparent drug resistance performance, the influence of different biofilm states on the actual drug resistance performance of the bacteria is quantified, and then the actual drug resistance performance of the bacteria in the biofilm is obtained, so that the actual drug resistance performance is highly matched with the current biofilm state of the bacteria, thereby improving the accuracy of the actual drug resistance performance.

[0055] Optionally, the system further includes:

[0056] Determine whether the antibiotic needs to be replaced based on the pathogen type information and the actual drug resistance performance;

[0057] If the antibiotic needs to be replaced, the information on replacing the antibiotic is determined based on the pathogenic bacteria type information;

[0058] If the antibiotic does not need to be changed, determining the difference in drug resistance performance according to the actual drug resistance performance and the apparent drug resistance performance;

[0059] The combined medication information is determined based on the differences in drug resistance and the pathogenic bacteria type information.

[0060] Through the above technical scheme, it is determined whether the antibiotic needs to be replaced based on the pathogen type information and the actual drug resistance performance. If the antibiotic needs to be replaced, the replacement antibiotic information is determined directly based on the pathogen type information. If the antibiotic does not need to be replaced, the difference in drug resistance performance is determined based on the actual drug resistance performance and the apparent drug resistance performance, and the combined medication information is determined based on the difference in drug resistance performance and the pathogen type information. The medication strategy is determined based on the actual state of bacteria affected by the biofilm, so that the medication strategy for dealing with pathogens is more effective. BRIEF DESCRIPTION OF THE DRAWINGS

[0061] In order to more clearly illustrate the embodiments of the present application or the technical solutions in the prior art, a brief introduction will be given below to the drawings required for use in the embodiments or the description of the prior art. Obviously, the drawings described below are some embodiments of the present application. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying any creative labor.

[0062] Figure 1 A schematic diagram of an application scenario provided for an embodiment of the present application;

[0063] Figure 2 A flowchart of a data processing system based on bacterial resistance monitoring provided in one embodiment of the present application. DETAILED DESCRIPTION

[0064] In order to make the purpose, technical scheme and advantages of the embodiments of the present application clearer, the technical scheme in the embodiments of the present application will be clearly and completely described below in conjunction with the drawings in the embodiments of the present application. Obviously, the described embodiments are part of the embodiments of the present application, not all of the embodiments. Based on the embodiments in the present application, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of this application.

[0065] In addition, the term "and / or" in this article is only a description of the association relationship of associated objects, indicating that there can be three relationships. For example, A and / or B can represent: A exists alone, A and B exist at the same time, and B exists alone. In addition, the character " / " in this article, unless otherwise specified, generally means that the associated objects before and after are in an "or" relationship.

[0066] The embodiments of the present application are further described in detail below in conjunction with the drawings in the specification.

[0067] Existing bacterial resistance monitoring technologies are unable to accurately assess the current bacterial resistance when there are objective differences between bacterial resistance in animals and in vitro, resulting in misjudgment of the bacterial resistance itself, which in turn leads to countermeasures with extremely limited effects.

[0068] Based on this, the present application provides a data processing system based on bacterial resistance monitoring. By analyzing biofilm marker information and pathogenic bacteria type information, it is determined whether the pathogenic bacteria have formed a biofilm. If the pathogenic bacteria have formed a biofilm, the biofilm marker information is analyzed to determine the real-time biofilm state, and then by analyzing the real-time biofilm state and the apparent resistance performance, the actual resistance performance of the pathogenic bacteria is determined, and the actual resistance performance of the bacteria in the biofilm is clarified, so as to avoid the resistance performance of the bacteria affected by the biofilm from misleading the veterinary treatment plan adjustment, and improve the effectiveness of the subsequent treatment plan. At the same time, it can significantly reduce the abuse of antibiotics, thereby curbing the further development of bacterial resistance.

[0069] Figure 1 A schematic diagram of an application scenario provided by this application. In the process of monitoring bacterial resistance in animals, the system provided by this application is used to comprehensively analyze biofilm marker information, pathogenic bacteria type information, and antibiotic destruction product information, and then the actual resistance performance of the pathogenic bacteria is obtained, and the actual resistance performance is provided to veterinarians for reference.

[0070] Specifically, the system provided by the present application is mounted in any server, and the server communicates with a number of implantable biosensors. The server obtains and analyzes the biofilm marker information and pathogenic bacteria type information provided by the implantable biosensors, and determines whether the pathogenic bacteria have formed a biofilm. If the pathogenic bacteria have formed a biofilm, the biofilm marker information is analyzed to determine the real-time biofilm state, and then the actual resistance performance of the pathogenic bacteria is determined by analyzing the real-time biofilm state and the apparent resistance performance, and the actual resistance performance is output for veterinary reference, which clarifies the actual resistance performance of bacteria in the biofilm, avoids the resistance performance of bacteria affected by the biofilm from misleading the veterinary treatment plan adjustment, improves the effectiveness of subsequent treatment plans, and can significantly reduce the abuse of antibiotics, thereby curbing the further development of bacterial resistance. The specific implementation method can refer to the following embodiments.

[0071] Figure 2 This is a flow chart of a data processing system based on bacterial resistance monitoring provided by an embodiment of the present application. The system of this embodiment can be applied to the server in the above scenario. Figure 2 As shown, the system comprises:

[0072] S201. Obtain biofilm marker information and pathogenic bacteria type information, analyze the biofilm marker information and pathogenic bacteria type information, and determine whether the pathogenic bacteria in the animal body form a biofilm.

[0073] Biofilm marker information can be molecular information or material information used to reflect the characteristics of bacterial biofilms, such as extracellular polysaccharide information. Biofilm marker information can be obtained by monitoring animals through a number of implanted biosensors.

[0074] The pathogenic bacteria type information may be the type of bacteria that currently needs to be monitored, and the pathogenic bacteria type information is obtained through a number of implantable biosensors.

[0075] Specifically, when bacteria are in the body of an animal, they will form a biofilm due to the influence of the bacteria's own characteristics, the availability of nutrients and local environmental conditions. The biofilm produces a barrier effect on the periphery of the bacteria, affecting the penetration of antibiotics into the bacteria. In addition, the bacteria in the biofilm are usually in a dormant or low metabolic state, which will further inhibit the effect of antibiotics. Because the mechanism of most antibiotics is to target actively dividing bacteria, the drug resistance of bacteria in the biofilm is significantly affected by the biofilm. When monitoring and evaluating bacterial resistance, if the drug resistance of bacteria in the biofilm is directly used as the actual drug resistance of bacteria, it is easy to increase the antibiotic dosage or need to directly The misjudgment of changing antibiotics and ignoring more effective combination drug strategies lead to the abuse of antibiotics, which not only increases the physical burden of bacterial host animals, but also further increases bacterial resistance. In the process of biofilm formation by different types of bacteria, a series of highly correlated markers will be produced. These markers can reflect whether the current type of bacteria has produced biofilm. Therefore, when monitoring bacterial resistance, it is necessary to use mathematical analysis to analyze the biofilm marker information and pathogenic bacteria type information, and then determine whether the bacteria in the current animal have formed a biofilm, which provides an important basis for the subsequent accurate assessment of the actual drug resistance of bacteria in the biofilm.

[0076] S202: If the pathogenic bacteria have formed a biofilm, analyze the biofilm marker information to determine the real-time biofilm status.

[0077] The real-time biofilm state may be a state corresponding to the current development stage of the bacterial peripheral biofilm, such as an attached state, an aggregated state, and the like.

[0078] Specifically, after bacteria form a biofilm, the biofilm is not static, but will enter different stages as the bacteria develop. The states exhibited by the biofilm at different development stages are significantly different. These significant differences will affect the drug resistance of bacteria in the biofilm. For example, the attached state is the initial development stage of the biofilm. At this time, the biofilm has just been formed, and the barrier effect of the biofilm in the attached state on antibiotics is relatively weak. Then, when the biofilm is in the attached state, it can be considered that the actual drug resistance of the bacteria is less affected by the biofilm. By determining the state of the biofilm, the evaluation of the actual drug resistance of the bacteria can be made more accurate. The state of the biofilm can be reflected by the content of different markers in the biofilm marker information. Therefore, it is necessary to analyze the biofilm marker information through mathematical analysis to determine the real-time biofilm state, so as to provide a basis for the biofilm state information for the subsequent evaluation of the actual drug resistance of the bacteria.

[0079] S203, obtaining information on the destruction products of antibiotics, and determining the apparent drug resistance of the pathogenic bacteria based on the information on the destruction products of antibiotics and information on the type of pathogenic bacteria.

[0080] The information of antibiotic destruction products may be information of a number of products that have changed due to the destructive effects of antibiotics, and the information of antibiotic destruction products may reflect the effectiveness of antibiotics.

[0081] Apparent resistance can be manifested as resistance exhibited by bacteria in animals without considering the influence of biofilm.

[0082] Specifically, when antibiotics destroy and inhibit bacteria, a variety of products are produced. By monitoring and analyzing these products, the effect of the current antibiotics on the bacteria corresponding to the pathogenic bacteria type information can be reflected, and then the apparent drug resistance of the bacteria can be reversely confirmed, providing an important data basis for the subsequent determination of the accurate actual drug resistance of bacteria in combination with the biofilm status.

[0083] S204, analyzing the real-time biofilm status and apparent drug resistance performance, determining the actual drug resistance performance of the pathogenic bacteria, and outputting the actual drug resistance performance for reference by the veterinarian.

[0084] The actual drug resistance performance can be the actual drug resistance performance of bacteria obtained on the basis of the apparent drug resistance performance of bacteria after considering the effect of biofilm state on the drug resistance performance of bacteria.

[0085] Specifically, through mathematical analysis, on the basis of apparent resistance performance, the impact of real-time biofilm status on bacterial resistance performance is quantified, and then the actual resistance performance of bacteria in the biofilm is obtained. Through human-computer interaction equipment, the actual resistance performance is output, providing accurate bacterial resistance information for veterinarians to perform subsequent treatment of bacterial host animals.

[0086] Through the method of this embodiment, biofilm marker information and pathogenic bacteria type information are analyzed to determine whether the pathogenic bacteria have formed a biofilm. If the pathogenic bacteria have formed a biofilm, the biofilm marker information is analyzed to determine the real-time biofilm state. Then, by analyzing the real-time biofilm state and the apparent drug resistance performance, the actual drug resistance performance of the pathogenic bacteria is determined, and the actual drug resistance performance of the bacteria in the biofilm is clarified, so as to avoid misleading the veterinary treatment plan adjustment due to the drug resistance performance of bacteria affected by the biofilm. While improving the effectiveness of subsequent treatment plans, it can significantly reduce the abuse of antibiotics, thereby curbing the further development of bacterial resistance.

[0087] In some embodiments, extracellular polysaccharide information is screened based on pathogenic bacteria type information to determine the polysaccharide information of the pathogenic bacteria; the polysaccharide information of the pathogenic bacteria is analyzed to determine the polysaccharide quantity information, polysaccharide particle distribution information and polysaccharide cross-linking information of the pathogenic bacteria; a biofilm index is determined based on the polysaccharide quantity information, polysaccharide particle distribution information and polysaccharide cross-linking information; the biofilm index is compared with a preset biofilm threshold, and if the biofilm index is greater than the preset biofilm threshold, it is determined that the pathogenic bacteria in the animal have formed a biofilm.

[0088] The biofilm marker information includes extracellular polysaccharide information, and the extracellular polysaccharide information can be information about sugar substances secreted by cells into their external environment.

[0089] The pathogenic bacteria polysaccharide information may be information on polysaccharide substances secreted by pathogenic bacteria in the extracellular polysaccharide information. The pathogenic bacteria polysaccharide information may be obtained by matching the extracellular polysaccharide information with information in a preset pathogenic bacteria polysaccharide database for storing information on different types of pathogenic bacteria polysaccharides.

[0090] The polysaccharide quantity information may be the polysaccharide quantity information in the polysaccharide information of pathogenic bacteria within a fixed analysis period.

[0091] The polysaccharide particle distribution information may be the distribution of polysaccharide particles produced by pathogenic bacteria in the host within a fixed analysis period.

[0092] The polysaccharide cross-linking information may be the cross-linking structure information formed by the polysaccharides produced by pathogenic bacteria within a fixed analysis period.

[0093] The biofilm index may be a quantitative index for reflecting the state of bacterial biofilm formation.

[0094] The preset biofilm threshold may be threshold data used to determine whether the current biofilm index represents that bacteria have formed a biofilm. The preset biofilm threshold may be obtained by analyzing historical data.

[0095] Specifically, the components of bacterial biofilms are mainly extracellular polysaccharides secreted by bacteria. By analyzing the polysaccharide information of pathogenic bacteria, it can be indirectly reflected whether the current pathogenic bacteria have formed a biofilm. Among them, the polysaccharide quantity information can directly reflect the biofilm-forming ability of pathogenic bacteria. A large amount of polysaccharides usually means that the pathogenic bacteria have a strong biofilm-forming ability. It can be inferred that the current pathogenic bacteria have a high probability of forming a biofilm. If the polysaccharide particle diameter in the polysaccharide particle distribution information is highly uniform, it can be considered that a uniform biofilm has been formed on the bacterial surface. Furthermore, the polysaccharide cross-linking information can reflect the integrity of the bacterial peripheral biofilm. If the degree of cross-linking of the polysaccharides secreted by the bacteria is high, it can be considered that a complete biofilm has been formed on the bacterial surface. Therefore, it is necessary to comprehensively consider the polysaccharide quantity information, polysaccharide particle distribution information and polysaccharide cross-linking information of the pathogenic bacteria, and quantify the biofilm index reflecting the biofilm formation state of the pathogenic bacteria through mathematical analysis, and then compare the biofilm index with the preset biofilm threshold. If the biofilm index is greater than the preset biofilm threshold, it can be accurately and comprehensively determined that the pathogenic bacteria in the animal have formed a biofilm.

[0096] Through the method provided in this embodiment, the extracellular polysaccharide information is screened according to the pathogenic bacteria type information to determine the pathogenic bacteria polysaccharide information, and then the polysaccharide quantity information, polysaccharide particle distribution information and polysaccharide cross-linking information of the pathogenic bacteria are obtained. After comprehensive analysis of the above information, the biofilm index is determined, and the biofilm index is compared with the preset biofilm threshold. If the biofilm index is greater than the preset biofilm threshold, it is determined that the pathogenic bacteria in the animal have formed a biofilm, so that the biofilm index can comprehensively reflect the biofilm formation state outside the current pathogenic bacteria, improve the accuracy of judging whether the pathogenic bacteria have formed a biofilm, and then ensure the accuracy of the premise for the subsequent evaluation of the actual drug resistance performance of the pathogenic bacteria in the biofilm.

[0097] In some embodiments, the average polysaccharide amount and the maximum polysaccharide amount are determined based on the polysaccharide quantity information; the average particle diameter and the particle diameter standard deviation are determined based on the polysaccharide particle distribution information; the average cross-linking score, the maximum cross-linking score and the minimum cross-linking score are determined based on the polysaccharide cross-linking information; and the biofilm index is determined, specifically, the following formula (1):

[0098] (1)

[0099] in, is the biofilm index, is the average polysaccharide content, is the maximum amount of polysaccharide, The preset quantity affects the weight. is the average particle diameter, is the standard deviation of particle diameter, To preset particle influence weights, is the average cross-linking score, is the maximum value of the cross-linking score, is the minimum cross-linking score, Preset cross-link influence weight.

[0100] The average polysaccharide amount may be an average value of the polysaccharide amount within a fixed analysis period, and the fixed analysis period may be a time period corresponding to when the antibiotic blood concentration in the animal reaches the highest.

[0101] The maximum polysaccharide amount can be the maximum value of the polysaccharide amount within a fixed analysis period.

[0102] The average particle diameter may be an average value of polysaccharide particle diameters in the polysaccharide particle distribution information.

[0103] The particle diameter standard deviation can be data used to describe the differences between polysaccharide particle diameters. The smaller the particle diameter standard deviation, the higher the consistency of the particle diameter.

[0104] The average cross-linking score may be an average value of the polysaccharide cross-linking degree in the polysaccharide cross-linking information.

[0105] The maximum value of the cross-linking score may be the maximum value of the polysaccharide cross-linking degree in the polysaccharide cross-linking information.

[0106] The minimum cross-linking score can be the minimum cross-linking degree of polysaccharides in the cross-linking information of polysaccharides.

[0107] The preset quantity influence weight may be a preset weight coefficient used to reflect the degree of influence of the polysaccharide quantity on biofilm formation, and the preset quantity influence weight may be obtained by analyzing experimental data.

[0108] The preset particle influence weight can be a preset weight coefficient used to reflect the influence of polysaccharide particle distribution on biofilm formation. The preset particle influence weight can be obtained by analyzing experimental data.

[0109] The preset cross-linking influence weight may be a preset weight coefficient used to reflect the influence of the polysaccharide cross-linking degree on biofilm formation, and the preset cross-linking influence weight may be obtained by analyzing experimental data.

[0110] Specifically, the information on the number of polysaccharides, the distribution of polysaccharide particles, and the cross-linking of polysaccharides can indirectly reflect the formation of bacterial biofilms. , and The polysaccharide quantity information, polysaccharide particle distribution information and polysaccharide cross-linking information were standardized and normalized respectively, and the biofilm index affected by the polysaccharide quantity information, polysaccharide particle distribution information and polysaccharide cross-linking information was calculated by weighted sum.

[0111] It should be noted that the number of polysaccharides directly affects the ability of bacteria to form biofilms. The formation of biofilms usually requires a large amount of extracellular polysaccharides, which provide matrix and structural support. A large number of polysaccharides help the adhesion between bacteria and between bacteria and the surface, and promote the stability of the biofilm. Therefore, the proportion of the preset quantity impact weight should be significantly greater than the preset particle impact weight and the preset cross-linking impact weight.

[0112] At the same time, since the degree of cross-linking of polysaccharides affects the mechanical strength and stability of the biofilm, highly cross-linked polysaccharides can form a stronger three-dimensional network, providing better structural support for the biofilm. Changes in the degree of cross-linking can significantly affect the formation and maintenance of the biofilm, and the distribution of polysaccharide particles affects its overall function in the biofilm, but compared with the number and degree of cross-linking, its influence is more minor. Polysaccharides with good particle distribution can increase the uniformity and stability of the biofilm, but even if the particle distribution is poor, if the number and degree of cross-linking are appropriate, a biofilm can still be formed. Therefore, the proportion of the preset particle influence weight should be significantly greater than the preset cross-linking influence weight.

[0113] Through the method provided in this embodiment, mathematical analysis methods are used to standardize and normalize the polysaccharide quantity information, polysaccharide particle distribution information and polysaccharide cross-linking information through mathematical formulas, and the biofilm index is calculated by weighted sum, so that the biofilm index is more comprehensive and accurate, thereby improving the accuracy of judging whether bacteria have formed a biofilm.

[0114] In some embodiments, the polysaccharide information of pathogenic bacteria is analyzed to determine the polysaccharide viscosity, polysaccharide protein content, polysaccharide charge characteristics and polysaccharide hydration index; the real-time structural state index of the pathogenic bacteria is determined based on the polysaccharide viscosity and the polysaccharide protein content; the real-time functional state index of the pathogenic bacteria is determined based on the polysaccharide charge characteristics and the polysaccharide hydration index; the biofilm state index is determined based on the real-time structural state index and the real-time structural state index; and the biofilm state is determined based on the biofilm state index.

[0115] The polysaccharide viscosity may be data reflecting the viscosity of extracellular polysaccharides secreted by pathogenic bacteria.

[0116] The polysaccharide protein content may be data reflecting the protein content in the extracellular polysaccharide secreted by pathogenic bacteria.

[0117] The polysaccharide charge property may be data reflecting the charge characteristics exhibited by extracellular polysaccharides.

[0118] The polysaccharide hydration index may be data reflecting the solubility of extracellular polysaccharide in an aqueous phase.

[0119] The real-time structural state index may be data reflecting the physical state of the biofilm.

[0120] The real-time functional status index may be data reflecting the functional status of the biofilm.

[0121] The biofilm status index may be data indicating the current bacterial biofilm status.

[0122] Specifically, it can be seen from the aforementioned embodiments that the state of the biofilm has a significant impact on the drug resistance exhibited by bacteria, and the state of the biofilm is mainly affected by the comprehensive influence of polysaccharide viscosity, polysaccharide protein content, polysaccharide charge characteristics and polysaccharide hydration index, among which the polysaccharide viscosity reflects the flow characteristics and internal structure stability of the biofilm. A higher viscosity value usually means that the biofilm state is stable. The polysaccharide protein content can affect the overall structure and stability of the biofilm. Proteins enhance the stability of the biofilm structure by binding to polysaccharide molecules. Polysaccharide viscosity and polysaccharide protein content can jointly reflect the real-time structural state of the biofilm.

[0123] The charged properties of polysaccharides can affect their interactions with other molecules, such as their ability to bind to cell surfaces. The charge properties of polysaccharides can affect the biocompatibility of biofilms and their interactions with host cells. The hydration capacity of polysaccharides directly affects their solubility in the biological environment and their interactions with water molecules. The charge properties of polysaccharides and the polysaccharide hydration index simultaneously affect the functional performance of biofilms in cell communication. The charge properties of polysaccharides and the polysaccharide hydration index can jointly reflect the real-time functional status of biofilms.

[0124] Through mathematical analysis, the real-time structural state index and real-time functional state index are obtained according to the polysaccharide viscosity, polysaccharide protein content, polysaccharide charge characteristics and polysaccharide hydration index respectively. The biofilm index is determined by combining the real-time structural state index and the real-time functional state index, and the biofilm state is determined according to the range of the biofilm index.

[0125] By the method provided in this embodiment, the polysaccharide viscosity, polysaccharide protein content, polysaccharide charge characteristics and polysaccharide hydration index are analyzed to obtain the real-time structural state index and the real-time functional state index respectively, and the real-time structural state index and the real-time functional state index are combined to determine the biofilm index, and then determine the biofilm state, so that the obtained biofilm state conforms to the actual situation of the bacterial peripheral biofilm, thereby improving the accuracy of the subsequent analysis of the actual bacterial resistance process based on the biofilm state.

[0126] In some embodiments, the real-time structural state index of pathogenic bacteria is determined based on the polysaccharide viscosity and polysaccharide protein content, specifically the following formula (2):

[0127] (2)

[0128] in, is the real-time structural status index, is the preset infrastructure status index, is the preset viscosity influence coefficient, For polysaccharide viscosity, To preset the protein influence coefficient, To preset the protein impact index, For the polysaccharide protein content.

[0129] The preset basic structure state index may be a basic biofilm structure state index of the current type of bacteria, and the preset basic structure state index may be obtained by analyzing experimental data of different types of bacteria.

[0130] The preset viscosity influence coefficient may be preset data used to express the degree of influence of polysaccharide viscosity on the real-time structural state of the biofilm, and the preset viscosity influence coefficient may be obtained by analyzing biofilm experimental data.

[0131] The preset protein influence coefficient may be preset data used to express the linear influence of the polysaccharide protein content on the real-time structural state of the biofilm. The preset protein influence coefficient may be obtained by analyzing biofilm experimental data.

[0132] The preset protein impact index may be preset data used to express the nonlinear impact of polysaccharide protein content on the real-time structural state of the biofilm. The preset protein impact index may be obtained by analyzing biofilm experimental data.

[0133] Specifically, through formula (2) Describes the nonlinear effect of linearized polysaccharide viscosity on the real-time structural state index, eliminates the influence of too high or too low polysaccharide viscosity values ​​on the results, and The nonlinear rapid growth effect of polysaccharide protein content on the real-time structural state index is described, reflecting the key adhesion and structural role of polysaccharide protein in the biofilm. The nonlinear effects of polysaccharide viscosity and polysaccharide protein content on the biofilm structural state are integrated through formula (2), thereby obtaining an accurate real-time structural state index.

[0134] Through the method provided in this embodiment, a mathematical formula is used to comprehensively describe the nonlinear effects of polysaccharide viscosity and polysaccharide protein content on the structural state of the biofilm, thereby obtaining a real-time structural state index that reflects the real-time structural state of the biofilm, thereby improving the accuracy and comprehensiveness of the biofilm state determination process.

[0135] In some embodiments, the real-time functional status index of pathogenic bacteria is determined based on the polysaccharide charge characteristics and the polysaccharide hydration index, specifically the following formula (3):

[0136] (3)

[0137] in, is the real-time functional status index, is the preset charge influence coefficient, is the preset charge fluctuation coefficient, is the charge characteristic of polysaccharides, is the preset hydration influence coefficient, is the preset hydration fluctuation coefficient, is the polysaccharide hydration index; the biofilm state index is determined according to the real-time structural state index and the real-time functional state index, specifically the following formula (4):

[0138] (4)

[0139] in, is the biofilm status index, is the real-time structural status index, It is the real-time functional status index.

[0140] The preset charge influence coefficient may be preset data used to express the degree of influence of the charge characteristics of the polysaccharide on the real-time functional state of the biofilm, and the preset charge influence coefficient may be obtained by analyzing the biofilm experimental data.

[0141] The preset charge fluctuation coefficient may be preset data for expressing the degree of fluctuation of the charge characteristics of the polysaccharide.

[0142] The preset hydration influence coefficient may be preset data used to express the degree of influence of the polysaccharide hydration capacity on the real-time functional state of the biofilm, and the preset hydration influence coefficient may be obtained by analyzing biofilm experimental data.

[0143] The preset hydration fluctuation coefficient may be preset data for expressing the degree of fluctuation of the hydration capacity of the polysaccharide.

[0144] Specifically, through formula (3) Describe the effects of periodic fluctuations in polysaccharide charge properties in biofilms on real-time functional status indices and The indirect correlation effect of the stable fluctuation of polysaccharide hydration index in biofilm on the real-time functional status index is described, and the influence of polysaccharide charge characteristics and polysaccharide hydration index on the real-time functional status index is comprehensively considered to quantify the accurate real-time functional status index.

[0145] Through the method of this embodiment, on the basis of the polysaccharide charge characteristics and the polysaccharide hydration index, the influence of the periodic fluctuation of the polysaccharide charge characteristics and the stable fluctuation of the polysaccharide hydration index on the real-time functional status index is considered, and the mathematical formula is used to comprehensively consider the influence of the polysaccharide charge characteristics and the polysaccharide hydration index on the real-time functional status index, and the accurate real-time functional status index is quantified to improve the comprehensiveness of the real-time functional status index.

[0146] In some embodiments, according to the pathogen type information, the antibiotic destruction product information is screened to determine the pathogen metabolite information; based on the pathogen type information, the pathogen metabolite information is subjected to drug resistance association analysis to determine the apparent drug resistance performance.

[0147] The information on pathogenic bacteria metabolites may be information on compounds produced by metabolic changes in pathogenic bacteria under the action of antibiotics.

[0148] Specifically, in the process of determining the apparent drug resistance of pathogenic bacteria, the metabolite information of pathogenic bacteria can reflect the resistance of pathogenic bacteria to current antibiotics. This is because after being affected by antibiotics, pathogenic bacteria will produce specific enzymes, such as β-lactam enzyme, to degrade or modify antibiotics, thereby causing them to develop drug resistance. At the same time, bacteria will produce more antioxidants, such as glutathione, to protect themselves from oxidative damage. The enhancement of this metabolic reaction is usually related to drug resistance. Therefore, through metabolite analysis technology, such as biosensors, the specific metabolite types in the pathogenic bacteria metabolite information can be analyzed to indirectly evaluate the bacterial resistance to relevant antibiotics and determine the apparent drug resistance of pathogenic bacteria.

[0149] Through the method provided in this embodiment, on the basis of the information on the type of pathogenic bacteria, the antibiotic destruction products are screened to determine the metabolite information of the pathogenic bacteria, and based on the metabolite information of the pathogenic bacteria, the apparent drug resistance performance is determined, so that the apparent drug resistance performance is consistent with the actual situation of the pathogenic bacteria, thereby improving the accuracy of the apparent drug resistance performance.

[0150] In some embodiments, several state activity coefficients and biofilm state information are determined according to the real-time biofilm state; based on the apparent drug resistance performance, the actual drug resistance performance is determined according to several state activity coefficients and biofilm state information.

[0151] The several state activity coefficients may be several coefficients used to express the directionality of the biofilm state.

[0152] The biofilm state information may be information that is highly correlated with the effect of the specific state of the biofilm on bacterial drug resistance, and the biofilm state information may be obtained through a biosensor according to the biofilm state.

[0153] Specifically, the real-time biofilm states include the attached state, aggregated state, stable state and diffused state. The difference in the state of the biofilm will cause significant differences in the actual resistance based on the apparent resistance. Specifically, when the biofilm state develops from the attached state to the aggregated state and the stable state, the impact of the biofilm on the resistance increases, and the impact is strongest in the stable state. This is because the biofilm has just taken shape in the attached state and has not yet fully matured. At this time, the biofilm in the attached state can only show a preliminary enhancement of bacterial resistance. When the biofilm develops to the aggregated state, the interaction between bacteria is strengthened, and the structure tends to be dense. The matrix tends to be rich, and the biofilm will further block the penetration of antibiotics to bacteria. When the biofilm develops to a stable state, the biofilm is fully mature, and the tolerance of the biofilm to antibiotics reaches its maximum. Furthermore, when the biofilm develops to the final diffusion state, some bacteria will break away from the biofilm and diffuse to other areas in a planktonic state. At this time, these bacteria are no longer protected by the biofilm and will be more sensitive to antibiotics. Therefore, based on the apparent resistance performance, according to several state activity coefficients and biofilm state information, mathematical analysis can be used to accurately obtain the actual resistance performance of pathogens in different biofilm states.

[0154] Through the method provided in this embodiment, according to the real-time biofilm state, several state activity coefficients and biofilm state information are determined, and on the basis of the apparent drug resistance performance, according to the several state activity coefficients and biofilm state information, the actual drug resistance performance is determined, and according to the different effects of different biofilm states on bacterial resistance, accurate actual drug resistance performance is obtained, so that the actual drug resistance performance conforms to the actual situation, thereby improving the accuracy and comprehensiveness of the actual drug resistance performance.

[0155] In some embodiments, based on the apparent drug resistance performance, the actual drug resistance performance is determined according to a number of state activity coefficients and biofilm state information, specifically the following formula (5):

[0156] (5)

[0157] in, For actual drug resistance performance, It is a manifestation of drug resistance. is the preset adhesion influence coefficient, is the attachment state activity coefficient, is the degree of adhesion, is the preset aggregation influence coefficient, is the degree of aggregation, is the aggregation activity coefficient, is the preset stability influence coefficient, is the effective concentration of antibiotics, is the steady-state activity coefficient, is the preset diffusion influence coefficient, is the diffusion film volume, is the diffusion activity coefficient.

[0158] Several state activity coefficients include the attached state activity coefficient, the aggregated state activity coefficient, the stable state activity coefficient and the diffused state activity coefficient.

[0159] Biofilm status information includes the degree of attachment, aggregation, antibiotic effective concentration and diffusion membrane volume.

[0160] The attachment state activity coefficient may be a coefficient value expressing whether the biofilm state points to the biofilm attachment state.

[0161] The aggregation state activity coefficient may be a coefficient value expressing whether the biofilm state points to the biofilm aggregation state.

[0162] The stable state activity coefficient may be a coefficient value expressing whether the biofilm state points to the biofilm stable state.

[0163] The diffusion state activity coefficient may be a coefficient value expressing whether the biofilm state points to the biofilm diffusion state.

[0164] The degree of attachment may be data reflecting the degree of attachment of the biofilm to the host.

[0165] The aggregation degree may be data reflecting the aggregation degree of the biofilm in the host.

[0166] The effective concentration of the antibiotic can be the effective concentration of the antibiotic in the host body determined based on the apparent drug resistance. The diffusion membrane quantity can be data reflecting the diffusion quantity of the biofilm in the host body.

[0167] The preset attachment influence coefficient may be a coefficient that expresses the degree of influence of the biofilm attachment state on the actual drug resistance performance, and the preset attachment influence coefficient may be obtained by analyzing biofilm experimental data.

[0168] The preset aggregation influence coefficient may be a coefficient that expresses the degree of influence of the biofilm aggregation state on the actual drug resistance performance, and the preset aggregation influence coefficient may be obtained by analyzing biofilm experimental data.

[0169] The preset stability influence coefficient may be a coefficient that expresses the degree of influence of the biofilm stability state on the actual drug resistance performance, and the preset stability influence coefficient may be obtained by analyzing biofilm experimental data.

[0170] The preset diffusion influence coefficient may be a coefficient that expresses the degree of influence of the diffusion state of the biofilm on the actual drug resistance performance, and the preset diffusion influence coefficient may be obtained by analyzing biofilm experimental data.

[0171] Specifically, the calculation process in formula (5) is controlled by the activity coefficient of the attached state, the activity coefficient of the aggregated state, the activity coefficient of the stable state and the activity coefficient of the diffuse state. When the biofilm state is in one of the attached state, the aggregated state, the stable state and the diffuse state, the activity coefficient corresponding to the biofilm state is 1, and the other activity coefficients are 0. Therefore, formula (5) can be used for targeted calculation according to different biofilm states. On the basis of the apparent drug resistance performance, the influence of different biofilm states on the actual drug resistance performance of bacteria is quantified, and the actual drug resistance performance of bacteria in the biofilm is obtained.

[0172] Through the method provided in this embodiment, the mathematical formula is controlled by the attachment state activity coefficient, the aggregation state activity coefficient, the stable state activity coefficient and the diffusion state activity coefficient for the current biofilm state of the bacteria. On the basis of the apparent drug resistance performance, the influence of different biofilm states on the actual drug resistance performance of the bacteria is quantified, and then the actual drug resistance performance of the bacteria in the biofilm is obtained, so that the actual drug resistance performance is highly matched with the current biofilm state of the bacteria, thereby improving the accuracy of the actual drug resistance performance.

[0173] In some embodiments, whether the antibiotic needs to be replaced is determined based on the pathogen type information and the actual drug resistance performance; if the antibiotic needs to be replaced, the antibiotic replacement information is determined based on the pathogen type information; if the antibiotic does not need to be replaced, the difference in drug resistance performance is determined based on the actual drug resistance performance and the apparent drug resistance performance; and the combination medication information is determined based on the difference in drug resistance performance and the pathogen type information.

[0174] The antibiotic replacement information may be relevant drug information of the antibiotic that needs to be replaced.

[0175] The combined medication information may be related drug information of antibiotics and biofilm destroying drugs.

[0176] Specifically, after the actual drug resistance of the pathogen is shown, the pathogen type information and the actual drug resistance performance are matched with the data in the preset drug resistance gradient database used to store the gradient data of the drug resistance performance of various pathogens to determine whether the antibiotics need to be replaced. If the antibiotics need to be replaced, the preset antibiotic database used to store the list of antibiotic drugs corresponding to various pathogens is queried according to the pathogen type information to determine the replacement antibiotic information. If the antibiotics do not need to be replaced, that is, the actual drug resistance performance of the current pathogens can still be treated with existing antibiotics, but the antibiotics are affected by the biofilm and the effect is not maximized. At this time, according to the actual drug resistance performance and the apparent drug resistance performance, the difference between the actual drug resistance performance and the apparent drug resistance performance is determined as the resistance performance difference. The resistance performance difference can be used to measure the required dosage of biofilm destroying drugs, and then according to the resistance performance difference and the pathogen type information, the preset biofilm destroying drug database used to store biofilm destroying drugs corresponding to different types of pathogens is queried to determine the combination drug information.

[0177] Through the method provided in this embodiment, it is determined whether the antibiotic needs to be replaced based on the pathogen type information and the actual drug resistance performance. If the antibiotic needs to be replaced, the antibiotic replacement information is determined directly based on the pathogen type information. If the antibiotic does not need to be replaced, the difference in drug resistance performance is determined based on the actual drug resistance performance and the apparent drug resistance performance, and the combined medication information is determined based on the difference in drug resistance performance and the pathogen type information. According to the actual state of bacteria affected by biofilm, the medication strategy is determined to make the medication strategy for dealing with pathogens more effective.

Claims

1. A data processing system based on bacterial resistance monitoring, characterized in that: include: Obtaining biofilm marker information and pathogenic bacteria type information, analyzing the biofilm marker information and the pathogenic bacteria type information, and determining whether the pathogenic bacteria in the animal body form a biofilm; If the pathogenic bacteria have formed a biofilm, analyzing the biofilm marker information to determine the real-time biofilm status; Obtaining information on antibiotic destruction products, and determining the apparent drug resistance performance of the pathogenic bacteria according to the information on the antibiotic destruction products and the type information of the pathogenic bacteria; Analyzing the real-time biofilm status and the apparent drug resistance performance, determining the actual drug resistance performance of the pathogenic bacteria, and outputting the actual drug resistance performance for reference by the veterinarian; The biofilm marker information includes extracellular polysaccharide information, and the analyzing the biofilm marker information and the pathogenic bacteria type information to determine whether the pathogenic bacteria in the animal body form a biofilm includes: According to the pathogenic bacteria type information, the extracellular polysaccharide information is screened to determine the pathogenic bacteria polysaccharide information; Analyzing the polysaccharide information of the pathogenic bacteria to determine the polysaccharide quantity information, polysaccharide particle distribution information and polysaccharide cross-linking information of the pathogenic bacteria; Determining a biofilm index according to the polysaccharide quantity information, the polysaccharide particle distribution information and the polysaccharide cross-linking information; Comparing the biofilm index with a preset biofilm threshold, and if the biofilm index is greater than the preset biofilm threshold, determining that the pathogenic bacteria in the animal have formed a biofilm; The analyzing the biofilm marker information to determine the real-time biofilm status includes: Analyzing the polysaccharide information of the pathogenic bacteria to determine the polysaccharide viscosity, polysaccharide protein content, polysaccharide charge characteristics and polysaccharide hydration index; Determining the real-time structural state index of the pathogenic bacteria according to the polysaccharide viscosity and the polysaccharide protein content; Determining the real-time functional status index of the pathogenic bacteria according to the polysaccharide charge characteristics and the polysaccharide hydration index; determining a biofilm state index according to the real-time structural state index and the real-time structural state index; Determining the biofilm state according to the biofilm state index; Determining the apparent drug resistance performance of the pathogenic bacteria according to the information of the antibiotic destruction products and the information of the type of the pathogenic bacteria includes: According to the pathogenic bacteria type information, the antibiotic destruction product information is screened to determine the pathogenic bacteria metabolite information; Based on the pathogen type information, performing drug resistance association analysis on the pathogen metabolite information to determine the apparent drug resistance performance; The analyzing the real-time biofilm state and the apparent drug resistance performance to determine the actual drug resistance performance of the pathogenic bacteria includes: According to the real-time biofilm state, determining a number of state activity coefficients and biofilm state information; Based on the apparent drug resistance performance, according to the several state activity coefficients and the biofilm state information, determining the actual drug resistance performance; The several state activity coefficients include an attached state activity coefficient, an aggregated state activity coefficient, a stable state activity coefficient and a diffused state activity coefficient, the biofilm state information includes an attachment degree, an aggregation degree, an effective antibiotic concentration and a diffusion membrane amount, and the actual drug resistance performance is determined based on the apparent drug resistance performance according to the several state activity coefficients and the biofilm state information, specifically as follows: R=R0·(1+α·θ·S A )·(1+β·N·S G )·(1+γ·C·S S )·(1-λ·B·S D ); Wherein, R is the actual drug resistance performance, R0 is the apparent drug resistance performance, α is the preset attachment influence coefficient, θ is the attachment state activity coefficient, S A is the degree of adhesion, β is the preset aggregation influence coefficient, N is the degree of aggregation, S G is the aggregation activity coefficient, γ is the preset stability influence coefficient, C is the effective concentration of the antibiotic, S S is the steady-state activity coefficient, λ is the preset diffusion influence coefficient, B is the diffusion membrane amount, S D is the diffusion state activity coefficient.

2. The system according to claim 1, characterized in that Determining the biofilm index according to the polysaccharide quantity information, the polysaccharide particle distribution information and the polysaccharide cross-linking information includes: Determining an average polysaccharide amount and a maximum polysaccharide amount according to the polysaccharide amount information; Determining an average particle diameter and a particle diameter standard deviation according to the polysaccharide particle distribution information; Determining an average cross-linking score, a maximum cross-linking score, and a minimum cross-linking score according to the polysaccharide cross-linking information; The biofilm index is determined by the following formula: Wherein, BFI is the biofilm index, C s is the average polysaccharide content, C max is the maximum polysaccharide amount, w C is the preset quantity influence weight, σ is the average particle diameter, μ is the standard deviation of the particle diameter, and w D To preset the particle influence weight, E s is the average cross-linking score, E max is the maximum value of the cross-linking score, E min is the minimum cross-linking score, w E Preset cross-link influence weight.

3. The system according to claim 1, characterized in that The real-time structural state index of the pathogenic bacteria is determined according to the polysaccharide viscosity and the polysaccharide protein content, specifically the following formula: SI=a+b·log(EV)+c·e d·EP ; Among them, SI is the real-time structural state index, a is the preset basic structural state index, b is the preset viscosity influence coefficient, EV is the polysaccharide viscosity, c is the preset protein influence coefficient, d is the preset protein influence index, and EP is the polysaccharide protein content.

4. The system according to claim 3, characterized in that The real-time functional status index of the pathogenic bacteria is determined according to the polysaccharide charge characteristics and the polysaccharide hydration index, specifically as follows: FI=k·sin(f·EC)+g·cos(h·EH); Wherein, FI is the real-time functional status index, k is the preset charge influence coefficient, f is the preset charge fluctuation coefficient, EC is the polysaccharide charge characteristic, g is the preset hydration influence coefficient, h is the preset hydration fluctuation coefficient, and EH is the polysaccharide hydration index; The biofilm state index is determined according to the real-time structural state index and the real-time functional state index, specifically the following formula: BSI = SI + FI; Among them, BSI is the biofilm status index, SI is the real-time structural status index, and FI is the real-time functional status index.

5. The system according to claim 1, characterized in that The system further comprises: Determine whether the antibiotic needs to be replaced based on the pathogen type information and the actual drug resistance performance; If the antibiotic needs to be replaced, the information on replacing the antibiotic is determined based on the pathogenic bacteria type information; If the antibiotic does not need to be changed, determining the difference in drug resistance performance according to the actual drug resistance performance and the apparent drug resistance performance; The combined medication information is determined based on the differences in drug resistance and the pathogenic bacteria type information.

Images